Technology Prognosis

tracking technologies before you have to make a decision

Tecentriq (Atezolizumab) for Urothelial Carcinoma

February 14, 2017

An intravenous programmed death ligand 1 checkpoint inhibitor for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, and for patients who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.